Accurately predicting the binding affinity between drugs and proteins is an essential step for computational drug discovery. Since graph neural networks (GNNs) have demonstrated remarkable success in various graph-related tasks, GNNs have been considered as a promising tool to improve the binding affinity prediction in recent years. However, most of the existing GNN architectures can only encode the topological graph structure of drugs and proteins without considering the relative spatial information among their atoms. Whereas, different from other graph datasets such as social networks and commonsense knowledge graphs, the relative spatial position and chemical bonds among atoms have significant impacts on the binding affinity. To this end, in this paper, we propose a diStance-aware Molecule graph Attention Network (S-MAN) tailored to drug-target binding affinity prediction. As a dedicated solution, we first propose a position encoding mechanism to integrate the topological structure and spatial position information into the constructed pocket-ligand graph. Moreover, we propose a novel edge-node hierarchical attentive aggregation structure which has edge-level aggregation and node-level aggregation. The hierarchical attentive aggregation can capture spatial dependencies among atoms, as well as fuse the position-enhanced information with the capability of discriminating multiple spatial relations among atoms. Finally, we conduct extensive experiments on two standard datasets to demonstrate the effectiveness of S-MAN.
The work for predicting drug and target affinity(DTA) is crucial for drug development and repurposing. In this work, we propose a novel method called GDGRU-DTA to predict the binding affinity between drugs and targets, which is based on GraphDTA, but we consider that protein sequences are long sequences, so simple CNN cannot capture the context dependencies in protein sequences well. Therefore, we improve it by interpreting the protein sequences as time series and extracting their features using Gate Recurrent Unit(GRU) and Bidirectional Gate Recurrent Unit(BiGRU). For the drug, our processing…
Huazhong Agricultural University（华中农业大学）；College of Informatics, Huazhong Agricultural University（华中农业大学信息学院）
The identification of drug-target binding affinity (DTA) has attracted increasing attention in the drug discovery process due to the more specific interpretation than binary interaction prediction. Recently, numerous deep learning-based computational methods have been proposed to predict the binding affinities between drugs and targets benefiting from their satisfactory performance. However, the previous works mainly focus on encoding biological features and chemical structures of drugs and targets, with a lack of exploiting the essential topological information from the drug-target affinity n…
Predicting the interaction between a compound and a target is crucial for rapid drug repurposing. Deep learning has been successfully applied in drug-target affinity (DTA) problem. However, previous deep learning-based methods ignore modeling the direct interactions between drug and protein residues. This would lead to inaccurate learning of target representation which may change due to the drug binding effects. In addition, previous DTA methods learn protein representation solely based on a small number of protein sequences in DTA datasets while neglecting the use of proteins outside of the D…
University of Illinois at Urbana Champaign（伊利诺伊大学厄巴纳-香槟分校）；Tsinghua University（清华大学）
Modeling the effects of mutations on the binding affinity plays a crucial role in protein engineering and drug design. In this study, we develop a novel deep learning based framework, named GraphPPI, to predict the binding affinity changes upon mutations based on the features provided by a graph neural network (GNN). In particular, GraphPPI first employs a well-designed pre-training scheme to enforce the GNN to capture the features that are predictive of the effects of mutations on binding affinity in an unsupervised manner and then integrates these graphical features with gradient-boosting tr…
University of Science and Technology of China（中国科学技术大学）；Baidu Research（百度研究院）；Baidu Inc.（百度公司）；Baidu Research USA（百度美国研究院）；Oregon State University（俄勒冈州立大学）；HWL Consulting LLC（HWL咨询有限责任公司）；Rutgers University（罗格斯大学）
Drug discovery often relies on the successful prediction of protein-ligand binding affinity. Recent advances have shown great promise in applying graph neural networks (GNNs) for better affinity prediction by learning the representations of protein-ligand complexes. However, existing solutions usually treat protein-ligand complexes as topological graph data, thus the biomolecular structural information is not fully utilized. The essential long-range interactions among atoms are also neglected in GNN models. To this end, we propose a structure-aware interactive graph neural network (SIGN) which…
ViDTA: Enhanced Drug-Target Affinity Prediction via Virtual Graph Nodes and Attention-based Feature Fusion
School of Software Engineering Huazhong University of Science；School of Cyber Science；Engineering Huazhong University of Science；Union Hospital, Tongji Medical College Huazhong University of Science
Protein binding affinity prediction under multiple substitutions applying eGNNs on Residue and Atomic graphs combined with Language model information: eGRAL
Skolkovo Institute of Science and Technology（斯科尔科沃科学技术学院）；Criteo AI（科韬人工智能）
Prediction of protein-ligand (PL) binding affinity remains the key to drug discovery. Popular approaches in recent years involve graph neural networks (GNNs), which are used to learn the topology and geometry of PL complexes. However, GNNs are computationally heavy and have poor scalability to graph sizes. On the other hand, traditional machine learning (ML) approaches, such as gradient-boosted decision trees (GBDTs), are lightweight yet extremely efficient for tabular data. We propose to use PL interaction features along with PL graph-level features in GBDT. We show that this combination outp…
Sun Yat-sen University（中山大学）；Guangdong Key Laboratory of Big Data Analysis and Processing（广东省大数据分析与处理重点实验室）；Microsoft Research Asia（微软亚洲研究院）；Fudan University（复旦大学）
The identification of active binding drugs for target proteins (termed as drug-target interaction prediction) is the key challenge in virtual screening, which plays an essential role in drug discovery. Although recent deep learning-based approaches achieved better performance than molecular docking, existing models often neglect certain aspects of the intermolecular information, hindering the performance of prediction. We recognize this problem and propose a novel approach named Intermolecular Graph Transformer (IGT) that employs a dedicated attention mechanism to model intermolecular informat…
Shenzhen University（深圳大学）；Tencent AI Lab（腾讯人工智能实验室）
Binding affinity prediction of three-dimensional (3D) protein ligand complexes is critical for drug repositioning and virtual drug screening. Existing approaches transform a 3D protein-ligand complex to a two-dimensional (2D) graph, and then use graph neural networks (GNNs) to predict its binding affinity. However, the node and edge features of the 2D graph are extracted based on invariant local coordinate systems of the 3D complex. As a result, the method can not fully learn the global information of the complex, such as, the physical symmetry and the topological information of bonds. To addr…
University of Pittsburgh（匹兹堡大学）；Carnegie Mellon University（卡内基梅隆大学）
To design a drug given a biological molecule by using deep learning methods, there are many successful models published recently. People commonly used generative models to design new molecules given certain protein. LiGAN was regarded as the baseline of deep learning model which was developed on convolutional neural networks. Recently, GraphBP showed its ability to predict innovative "real" chemicals that the binding affinity outperformed with traditional molecular docking methods by using a flow-based generative model with a graph neural network and multilayer perception. However, all those m…
Lawrence Livermore National Laboratory（劳伦斯利弗莫尔国家实验室）
Predicting accurate protein-ligand binding affinity is important in drug discovery but remains a challenge even with computationally expensive biophysics-based energy scoring methods and state-of-the-art deep learning approaches. Despite the recent advances in the deep convolutional and graph neural network based approaches, the model performance depends on the input data representation and suffers from distinct limitations. It is natural to combine complementary features and their inference from the individual models for better predictions. We present fusion models to benefit from different f…
Building explainable graph neural network by sparse learning for the drug-protein binding prediction
Luddy School of Informatics, Computing, and Engineering, Indiana University Bloomington（印第安纳大学伯明顿分校勒迪信息学、计算与工程学院）；School of Medicine, Indiana University（印第安纳大学医学院）
Efficient and effective drug-target binding affinity (DTBA) prediction is a challenging task due to the limited computational resources in practical applications and is a crucial basis for drug screening. Inspired by the good representation ability of graph neural networks (GNNs), we propose a simple-structured GNN model named SS-GNN to accurately predict DTBA. By constructing a single undirected graph based on a distance threshold to represent protein-ligand interactions, the scale of the graph data is greatly reduced. Moreover, ignoring covalent bonds in the protein further reduces the compu…
Indian Association for the Cultivation of Science（印度科学培育协会）
Development of new drugs is an expensive and time-consuming process. Due to the world-wide SARS-CoV-2 outbreak, it is essential that new drugs for SARS-CoV-2 are developed as soon as possible. Drug repurposing techniques can reduce the time span needed to develop new drugs by probing the list of existing FDA-approved drugs and their properties to reuse them for combating the new disease. We propose a novel architecture DeepGLSTM, which is a Graph Convolutional network and LSTM based method that predicts binding affinity values between the FDA-approved drugs and the viral proteins of SARS-CoV-2…
Bangladesh University of Engineering and Technology（孟加拉国工程技术大学）
The discovery of novel drug target (DT) interactions is an important step in the drug development process. The majority of computer techniques for predicting DT interactions have focused on binary classification, with the goal of determining whether or not a DT pair interacts. Protein ligand interactions, on the other hand, assume a continuous range of binding strength values, also known as binding affinity, and forecasting this value remains a difficulty. As the amount of affinity data in DT knowledge-bases grows, advanced learning techniques such as deep learning architectures can be used to…
College of Computer Science and Technology, Hunan University（湖南大学信息科学与工程学院）
Accurately predicting drug-target binding affinity (DTA) in silico is a key task in drug discovery. Most of the conventional DTA prediction methods are simulation-based, which rely heavily on domain knowledge or the assumption of having the 3D structure of the targets, which are often difficult to obtain. Meanwhile, traditional machine learning-based methods apply various features and descriptors, and simply depend on the similarities between drug-target pairs. Recently, with the increasing amount of affinity data available and the success of deep representation learning models on various doma…
Motivation: Prediction of the interaction affinity between proteins and compounds is a major challenge in the drug discovery process. WideDTA is a deep-learning based prediction model that employs chemical and biological textual sequence information to predict binding affinity. Results: WideDTA uses four text-based information sources, namely the protein sequence, ligand SMILES, protein domains and motifs, and maximum common substructure words to predict binding affinity. WideDTA outperformed one of the state of the art deep learning methods for drug-target binding affinity prediction, DeepDTA…
Computational models that accurately predict the binding affinity of an input protein-chemical pair can accelerate drug discovery studies. These models are trained on available protein-chemical interaction datasets, which may contain dataset biases that may lead the model to learn dataset-specific patterns, instead of generalizable relationships. As a result, the prediction performance of models drops for previously unseen biomolecules, $\textit{i.e.}$ the prediction models cannot generalize to biomolecules outside of the dataset. The latest approaches that aim to improve model generalizabilit…
Pakistan Institute of Engineering and Applied Sciences (PIEAS)（巴基斯坦工程与应用科学学院）
Determination of binding affinity of proteins in the formation of protein complexes requires sophisticated, expensive and time-consuming experimentation which can be replaced with computational methods. Most computational prediction techniques require protein structures which limit their applicability to protein complexes with known structures. In this work, we explore sequence based protein binding affinity prediction using machine learning. Our paper highlights the fact that the generalization performance of even the state of the art sequence-only predictor of binding affinity is far from sa…
AbAffinity: A Large Language Model for Predicting Antibody Binding Affinity against SARS-CoV-2
Department of Computer Science and Engineering,University of California, Riverside（加州大学河滨分校计算机科学与工程系）；Riggs School of Applied Life Sciences, Keck Graduate Institute, Claremont（克劳斯研究生院应用生命科学学院）
Tencent AI Lab（腾讯人工智能实验室）；The University of Hong Kong（香港大学）；Fudan University（复旦大学）
AI-aided drug discovery (AIDD) is gaining increasing popularity due to its promise of making the search for new pharmaceuticals quicker, cheaper and more efficient. In spite of its extensive use in many fields, such as ADMET prediction, virtual screening, protein folding and generative chemistry, little has been explored in terms of the out-of-distribution (OOD) learning problem with \emph{noise}, which is inevitable in real world AIDD applications. In this work, we present DrugOOD, a systematic OOD dataset curator and benchmark for AI-aided drug discovery, which comes with an open-source Pyth…
Identification of high affinity drug-target interactions is a major research question in drug discovery. Proteins are generally represented by their structures or sequences. However, structures are available only for a small subset of biomolecules and sequence similarity is not always correlated with functional similarity. We propose ChemBoost, a chemical language based approach for affinity prediction using SMILES syntax. We hypothesize that SMILES is a codified language and ligands are documents composed of chemical words. These documents can be used to learn chemical word vectors that repre…
Computational drug discovery strategies can be broadly placed in two categories: ligand-based methods which identify novel molecules by similarity with known ligands, and structure-based methods which predict molecules with high-affinity to a given 3D structure (e.g. a protein). However, ligand-based methods do not leverage information about the binding site, and structure-based approaches rely on the knowledge of a finite set of ligands binding the target. In this work, we introduce TarLig, a novel approach that aims to bridge the gap between ligand and structure-based approaches. We use the …
Binding Affinity Prediction: From Conventional to Machine Learning-Based Approaches
Department of Computer Science, University of Chicago（计算机科学系，芝加哥大学）；Argonne National Laboratory（阿贡国家实验室）；Pritzker School of Molecular Engineering, University of Chicago（分子工程学院，芝加哥大学）；Data Science Institute, University of Chicago（数据科学研究所，芝加哥大学）；Department of Computer Science, State University of New York at Albany（计算机科学系，纽约州立大学阿尔巴尼分校）；Department of Biomedical Informatics, Harvard Medical School（生物医学信息学系，哈佛医学院）；AI Lab, Princeton University（普林斯顿大学人工智能实验室）；Information Research, AbbVie Inc.（阿比联合公司信息研究部）；Toyota Technological Institute at Chicago（芝加哥丰田技术研究所）
IBM Research（IBM研究院）；MIT-IBM Watson AI Lab（MIT-IBM沃森人工智能实验室）；IBM Research Europe（IBM欧洲研究院）
The novel nature of SARS-CoV-2 calls for the development of efficient de novo drug design approaches. In this study, we propose an end-to-end framework, named CogMol (Controlled Generation of Molecules), for designing new drug-like small molecules targeting novel viral proteins with high affinity and off-target selectivity. CogMol combines adaptive pre-training of a molecular SMILES Variational Autoencoder (VAE) and an efficient multi-attribute controlled sampling scheme that uses guidance from attribute predictors trained on latent features. To generate novel and optimal drug-like molecules f…
Due to the contribution of drug-target binding kinetics to drug efficacy, there is a high level of interest in developing methods to predict drug-target binding kinetic parameters. During the review period, a wide range of enhanced sampling molecular dynamics simulation-based methods has been developed for computing drug-target binding kinetics and studying binding and unbinding mechanisms. Here, we assess the performance of these methods considering two benchmark systems in detail: mutant T4 lysozyme-ligand complexes and a large set of N-HSP90-inhibitor complexes. The results indicate that so…
One key task in virtual screening is to accurately predict the binding affinity ($\triangle$$G$) of protein-ligand complexes. Recently, deep learning (DL) has significantly increased the predicting accuracy of scoring functions due to the extraordinary ability of DL to extract useful features from raw data. Nevertheless, more efforts still need to be paid in many aspects, for the aim of increasing prediction accuracy and decreasing computational cost. In this study, we proposed a simple scoring function (called OnionNet-2) based on convolutional neural network to predict $\triangle$$G$. The pr…
FusionDTI: Fine-grained Binding Discovery with Token-level Fusion for Drug-Target Interaction
School of Computing Science（计算科学学院）；School of Cancer Sciences（癌症科学学院）；Cancer Research UK Scotland Institute（英国癌症研究苏格兰研究所）；University of Glasgow（格拉斯哥大学）
